Kuvatris Therapeutics, Inc.
DelistedCIK 1811623fmd_024PHPNB1K0DJSXFSYG8VZHM5VManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2024, 14 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Operating income
- (16)
- Net income
- (18)
Latest quarter · Q3 FY2024
Millions- Operating income
- (1)
- Net income
- (1)
Kuvatris Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $0 | 10-K 2024-03-11 · proof | |
| Operating income | -$16.1 million | -$10.6 million | 10-K 2024-03-11 · proof | |
| Net income | -$18.3 million | -$14.8 million | 10-K 2024-03-11 · proof | |
| Cash from operating activities | -$10.8 million | -$6.1 million | 10-K 2024-03-11 · proof | |
| Total assets | $5.7 million | $2.2 million | +157.7% | 10-K 2024-03-11 · proof |
| Total liabilities | $2.3 million | $2.1 million | +9.5% | 10-K 2024-03-11 · proof |
| Cash and cash equivalents | $4.7 million | $1.9 million | +147.7% | 10-K 2024-03-11 · proof |
- What was Kuvatris Therapeutics, Inc.'s revenue in fiscal 2023?
- Kuvatris Therapeutics, Inc. reported revenue of $0 for fiscal 2023 (the year ended Dec 31, 2023), against $0 the year before. Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What was Kuvatris Therapeutics, Inc.'s operating income in fiscal 2023?
- Kuvatris Therapeutics, Inc. reported operating income of -$16.1 million for fiscal 2023 (the year ended Dec 31, 2023), against -$10.6 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What was Kuvatris Therapeutics, Inc.'s net income in fiscal 2023?
- Kuvatris Therapeutics, Inc. reported net income of -$18.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$14.8 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What was Kuvatris Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
- Kuvatris Therapeutics, Inc. reported cash from operating activities of -$10.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$6.1 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What are Kuvatris Therapeutics, Inc.'s total assets?
- As of Dec 31, 2023, Kuvatris Therapeutics, Inc. reported total assets of $5.7 million, against $2.2 million a year earlier (+157.7%). Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What are Kuvatris Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2023, Kuvatris Therapeutics, Inc. reported total liabilities of $2.3 million, against $2.1 million a year earlier (+9.5%). Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What are Kuvatris Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Kuvatris Therapeutics, Inc. reported cash and cash equivalents of $4.7 million, against $1.9 million a year earlier (+147.7%). Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1811623&period_type=annual&limit=5"Information only, not investment advice.